Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies for Acute Coronary Syndrome: A Narrative Review
The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Monoclonal antibodies that inhibit proprotein convertase subtilisin/kexin type 9 (PCSK9) are an emerging therapy for dyslipidemia. Acute coronary events induce a dynamic increase of PCSK9 levels that may play a role in plaque vulnerability of both culprit and nonculprit coronary vessels. Growing evidence highlights a potential key role of PCSK9 antibodies in managing acute coronary syndrome. This review describes the influence of PCSK9 antibodies on plaque composition and instability, as well as the pharmacokinetic profile and the potential anti-inflammatory and antithrombotic mechanisms associated with PCSK9 inhibition that may confer benefits during the early phase of acute coronary syndrome. The authors posit a rationale for the use of PCSK9 antibodies in patients with acute coronary syndrome and highlight the need for further investigation in this area.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Colesevelam can also reduce glucose levels in hyperglycaemic patients [275].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [275]
In the citing paper
“A recent meta-analysis confirmed these findings.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [249]
In the citing paper
“A recent meta-analysis confirmed these findings.249”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [249]
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
The Nuclear Factor NF- B Pathway in Inflammation
Lawrence, T. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001651 · Cited by 4,898
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., de Bruyne, B., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,276
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296 · cited 1×
“The reduction in myocardial infarction seen in a recent meta-analysis and in higher-risk patients enrolled in the ODYSSEY LONG TERM (Long-term Safety and Tolerability of Alirocumab in High Cardiovascular Risk Patients with Hypercholesterolemia Not Adequately Controlled with Their Lipid Modifying Therapy) trial support…”
BackgroundAn endothelial receptor for oxidized low-density lipoprotein
Sawamura, T., Kume, N., Aoyama, T., Moriwaki, H., Hoshikawa, H., Aiba, Y., Tanaka, T., Miwa, S., Katsura, Y., Kita, T., et al. (1997) · Nature · doi:10.1038/386073a0 · Cited by 1,385 · cited 1×
“crease in oxLDL uptake, production of cell-surface adhesion molecules, and a state of oxidative stress and inflammation—2 key steps involved in the progression of atherosclerosis and destabilization of coronary plaque (32).”
BackgroundEhara, S., Ueda, M., Naruko, T., Haze, K., Itoh, A., Otsuka, M., Komatsu, R., Matsuo, T., Itabe, H., Takano, T., et al. (2001) · Circulation · doi:10.1161/01.cir.103.15.1955 · Cited by 781 · cited 1×
“Atherosclerotic plaque destabilization and rupture may be influenced by oxLDL, which induces the expression of molecules on endothelial cells that promote adhesion of monocytes (33).”
BackgroundLack of Interleukin-1β Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice
Kirii, H., Niwa, T., Yamada, Y., Wada, H., Saito, K., Iwakura, Y., Asano, M., Moriwaki, H., & Seishima, M. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000064374.15232.c3 · Cited by 748
Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype
Podrez, E. A., Byzova, T. V., Febbraio, M., Salomon, R. G., Ma, Y., Valiyaveettil, M., Poliakov, E., Sun, M., Finton, P. J., Curtis, B. R., et al. (2007) · Nature Medicine · doi:10.1038/nm1626 · Cited by 513
Poirier, S., Mayer, G., Benjannet, S., Bergeron, E., Marcinkiewicz, J., Nassoury, N., Mayer, H., Nimpf, J., Prat, A., & Seidah, N. G. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708098200 · Cited by 477 · cited 1×
“The enzyme facilitates degradation of the apolipoprotein E receptor-2 (30, 54, 55) and directly increases lipoprotein(a) concentration (56).”
BackgroundPark, S. W., Moon, Y.-A., & Horton, J. D. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m410077200 · Cited by 452 · cited 1×
“The enzyme facilitates degradation of the apolipoprotein E receptor-2 (30, 54, 55) and directly increases lipoprotein(a) concentration (56).”
BackgroundDavenport, P., & Tipping, P. G. (2003) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63471-2 · Cited by 444
Schwartz, G. G., Bessac, L., Berdan, L. G., Bhatt, D. L., Bittner, V., Diaz, R., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., et al. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.07.028 · Cited by 408
Navarese, E. P., Kołodziejczak, M., Schulze, V., Gurbel, P. A., Tantry, U., Lin, Y., Brockmeyer, M., Kandzari, D. E., Kubica, J. M., D'Agostino, R. B., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2957 · Cited by 404 · cited 2×
“They bind PCSK9 and prevent degradation of low-density lipoprotein (LDL) receptors, which increases LDL cholesterol clearance from the circulation (7, 8).”
BackgroundSelf-citationExogenous Interferon-γ Enhances Atherosclerosis in Apolipoprotein E−/− Mice
Whitman, S. C., Ravisankar, P., Elam, H., & Daugherty, A. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64820-1 · Cited by 378
Monocytes in Coronary Artery Disease and Atherosclerosis
Ghattas, A., Griffiths, H. R., Devitt, A., Lip, G. Y. H., & Shantsila, E. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.043 · Cited by 375 · cited 1×
“The PCSK9 antibodies modify the internal milieu of the coronary plaque by increasing inflammatory monocyte recruitment, a known cellular plaque component that triggers destabilization (35).”
BackgroundReduction in Lipoprotein(a) With PCSK9 Monoclonal Antibody Evolocumab (AMG 145)
Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Langslet, G., Bays, H., Blom, D., Eriksson, M., Dent, R., Wasserman, S. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.006 · Cited by 361 · cited 1×
“A detailed analysis of data from 4 phase 2, randomized, controlled trials showed that PCSK9 antibodies resulted in a dosedependent decrease in lipoprotein(a) levels (60).”
MethodRole of Oxidized LDL in Atherosclerosis
KITA, T., KUME, N., MINAMI, M., HAYASHIDA, K., MURAYAMA, T., SANO, H., MORIWAKI, H., KATAOKA, H., NISHI, E., HORIUCHI, H., et al. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03941.x · Cited by 277 · cited 1×
“These monocytes are subsequently phagocytized through scavenger receptors and accumulated in macrophages, which leads to the formation of foam cells (46).”
BackgroundFerri, N., Tibolla, G., Pirillo, A., Cipollone, F., Mezzetti, A., Pacia, S., Corsini, A., & Catapano, A. L. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.11.026 · Cited by 258
Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels
Dias, C. S., Shaywitz, A. J., Wasserman, S. M., Smith, B. P., Gao, B., Stolman, D. S., Crispino, C. P., Smirnakis, K. V., Emery, M. G., Colbert, A., et al. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.986 · Cited by 235 · cited 1×
“Drug administration results in a rapid decrease in PCKS9 levels, which is followed by a reduction in LDL cholesterol levels (38, 39).”
BackgroundCross-talk between LOX-1 and PCSK9 in vascular tissues
Ding, Z., Liu, S., Wang, X., Deng, X., Fan, Y., Shahanawaz, J., Shmookler Reis, R. J., Varughese, K. I., Sawamura, T., & Mehta, J. L. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv178 · Cited by 233 · cited 1×
“Recent studies indicate a cross-reaction between PCSK9 and lectin-like oxLDL receptor-1 that leads to a mutually amplified proinflammatory response (14).”
BackgroundTANG, Z., JIANG, L., PENG, J., REN, Z., WEI, D., WU, C., PAN, L., JIANG, Z., & LIU, L. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1072 · Cited by 208 · cited 1×
“Small interfering RNA of PCSK9 suppressed oxidized LDL (oxLDL)–induced inflammatory cytokine expression in macrophages (17), which suggests that PCSK9 may represent a novel therapeutic target (Table).”
BackgroundHulten, E., Jackson, J. L., Douglas, K., George, S., & Villines, T. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.17.1814 · Cited by 208
Romagnuolo, R., Scipione, C. A., Boffa, M. B., Marcovina, S. M., Seidah, N. G., & Koschinsky, M. L. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.611988 · Cited by 206 · cited 1×
“The enzyme facilitates degradation of the apolipoprotein E receptor-2 (30, 54, 55) and directly increases lipoprotein(a) concentration (56).”
BackgroundOxidant stress in mitochondrial DNA damage, autophagy and inflammation in atherosclerosis
Ding, Z., Liu, S., Wang, X., Khaidakov, M., Dai, Y., & Mehta, J. L. (2013) · Scientific Reports · doi:10.1038/srep01077 · Cited by 204
Kühnast, S., van der Hoorn, J. W. A., Pieterman, E. J., van den Hoek, A. M., Sasiela, W. J., Gusarova, V., Peyman, A., Schäfer, H.-L., Schwahn, U., Jukema, J. W., et al. (2014) · Journal of Lipid Research · doi:10.1194/jlr.m051326 · Cited by 204
PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway
Wu, C.-Y., Tang, Z.-H., Jiang, L., Li, X.-F., Jiang, Z.-S., & Liu, L.-S. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-011-1028-6 · Cited by 190 · cited 1×
“In the coronary plaque, PCSK9 inhibition decreases macrophages and necrotic core content and promotes apoptosis (15, 34).”
BackgroundIFN- γ Deficiency Exerts Gender-Specific Effects on Atherogenesis in Apolipoprotein E -/- Mice
Whitman, S. C., Ravisankar, P., & Daugherty, A. (2002) · Journal of Interferon & Cytokine Research · doi:10.1089/10799900260100141 · Cited by 176
Magwenzi, S., Woodward, C., Wraith, K. S., Aburima, A., Raslan, Z., Jones, H., McNeil, C., Wheatcroft, S., Yuldasheva, N., Febbriao, M., et al. (2015) · Blood · doi:10.1182/blood-2014-05-574491 · Cited by 174 · cited 1×
“Oxidized LDL can activate platelets (50, 51) via several mechanisms that include interaction with scavenger receptor A and CD36 (52).”
BackgroundChi, H., Messas, E., Levine, R. A., Graves, D. T., & Amar, S. (2004) · Circulation · doi:10.1161/01.cir.0000142085.39015.31 · Cited by 173
Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk
Tsimikas, S., & Witztum, J. L. (2001) · Circulation · doi:10.1161/01.cir.103.15.1930 · Cited by 155 · cited 1×
“During ACS, the available pool of oxLDL is increased due to atherosclerotic plaque rupture and release of necrotic core content to extracellular space (31).”
BackgroundLOX-1, mtDNA damage, and NLRP3 inflammasome activation in macrophages: implications in atherogenesis
Ding, Z., Liu, S., Wang, X., Dai, Y., Khaidakov, M., Deng, X., Fan, Y., Xiang, D., & Mehta, J. L. (2014) · Cardiovascular Research · doi:10.1093/cvr/cvu114 · Cited by 144
Navarese, E. P., Kowalewski, M., Andreotti, F., van Wely, M., Camaro, C., Kolodziejczak, M., Gorny, B., Wirianta, J., Kubica, J., Kelm, M., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.02.034 · Cited by 130 · cited 3×
“Randomized, controlled trials and a meta-analysis showed that statin therapy initiated before percutaneous coronary intervention (PCI) reduced periprocedural adverse events, which supports statin therapy before intervention in ACS (40).”
BackgroundResultSelf-citationPlatelet Activation by Oxidized Low Density Lipoprotein Is Mediated by Cd36 and Scavenger Receptor-A
Korporaal, S. J. A., Eck, M. V., Adelmeijer, J., IJsseldijk, M. J. W., Out, R., Lisman, T., Lenting, P. J., van Berkel, T. J. C., & Akkerman, J. N. (2007) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.107.150698 · Cited by 122 · cited 1×
“Oxidized LDL can activate platelets (50, 51) via several mechanisms that include interaction with scavenger receptor A and CD36 (52).”
BackgroundAlmontashiri, N. A. M., Vilmundarson, R. O., Ghasemzadeh, N., Dandona, S., Roberts, R., Quyyumi, A. A., Chen, H.-H., & Stewart, A. F. R. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106294 · Cited by 108 · cited 3×
“Multivariable logistic-regression analysis showed that plasma PCSK9 levels were an independent predictor of coronary artery disease (10).”
BackgroundRegulation of Vascular Smooth Muscle Cell Proliferation by Nuclear Factor-κB and Its Inhibitor, I-κB
Hoshi, S., Goto, M., Koyama, N., Nomoto, K.-I., & TANAKA, H. L. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.2.883 · Cited by 98
Plaque Rupture and Plaque Erosion
Burke, A. P., Farb, A., & Virmani, R. (1999) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1615543 · Cited by 93 · cited 1×
“Plaque vulnerability predisposes to rupture and erosion, which are substrates for coronary thrombosis (9).”
BackgroundIchikawa, T., Unoki‐Kubota, H., Sun, H., Shimoyamada, H., Marcovina, S. M., Shikama, H., Watanabe, T., & Fan, J. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64366-0 · Cited by 92 · cited 1×
“Lipoprotein(a) acts as a proinflammatory mediator that can trigger atherosclerotic plaque instability (57) by enhancing inflammation through expression of adhesion molecules on endothelial cells, chemotaxis of monocytes, and proliferation of smooth-muscle cells (58, 59).”
Backgroundfor the GRACE Investigators, Fox, K. A. A., Anderson, F. A., Goodman, S. G., Steg, P. G., Pieper, K. S., Quill, A., & Gore, J. M. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1302 · Cited by 89
From low-density lipoprotein to platelet activation
Akkerman, J. W. N. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.04.002 · Cited by 62 · cited 1×
“Oxidized LDL can activate platelets (50, 51) via several mechanisms that include interaction with scavenger receptor A and CD36 (52).”
BackgroundLunven, C., Paehler, T., Poitiers, F., Brunet, A., Rey, J., Hanotin, C., & Sasiela, W. J. (2014) · Cardiovascular Therapeutics · doi:10.1111/1755-5922.12093 · Cited by 60 · cited 2×
“Drug administration results in a rapid decrease in PCKS9 levels, which is followed by a reduction in LDL cholesterol levels (38, 39).”
BackgroundLi, S., Zhu, C.-G., Guo, Y.-L., Xu, R.-X., Zhang, Y., Sun, J., & Li, J.-J. (2015) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.25841 · Cited by 57 · cited 1×
“Moreover, plasma PCSK9 levels show positive and independent correlation with increased platelet count and plateletcrit (53).”
BackgroundZhang, Y., Liu, J., Li, S., Xu, R.-X., Sun, J., Tang, Y., & Li, J.-J. (2014) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-14-192 · Cited by 55
Orthner, C. L., Rodgers, G., & Fitzgerald, L. (1995) · Blood · doi:10.1182/blood.v86.2.436.bloodjournal862436 · Cited by 49 · cited 1×
“The PCSK9-induced nuclear factor- B pathway can enhance the thrombotic substrate in atherosclerotic plaques through upregulation of tissue factor (36).”
BackgroundZuckerbraun, B. S., McCloskey, C. A., Mahidhara, R. S., Kim, P. K. M., Taylor, B. S., & Tzeng, E. (2003) · Journal of Vascular Surgery · doi:10.1016/s0741-5214(03)00427-0 · Cited by 48
Li, S., Guo, Y., Xu, R., Zhang, Y., Zhu, C., Sun, J., Qing, P., Wu, N., & Li, J. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.04.224 · Cited by 46
Navarese, E. P., Servi, S. D., Gibson, C. M., Buffon, A., Castriota, F., Kubica, J., Petronio, A. S., Andreotti, F., & Luca, G. D. (2011) · QJM · doi:10.1093/qjmed/hcq258 · Cited by 45 · cited 2×
“First, optimal timing for administration is required to optimize plaque stabilization in relation to coronary intervention (40, 41).”
BackgroundSelf-citationMeta-Analysis of Apolipoprotein E Gene Polymorphism and Susceptibility of Myocardial Infarction
Xu, H., Li, H., Liu, J., Zhu, D., Wang, Z., Chen, A., & Zhao, Q. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104608 · Cited by 42 · cited 1×
“The enzyme facilitates degradation of the apolipoprotein E receptor-2 (30, 54, 55) and directly increases lipoprotein(a) concentration (56).”
BackgroundNavarese, E. P., Kołodziejczak, M. M., Dimitroulis, D., Wolff, G., Busch, H. L., Devito, F., Sionís, A., & Ciccone, M. M. (2015) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvv045 · Cited by 38
Self-citationThe NFκB inhibitory peptide, IκBα, prevents human vascular smooth muscle proliferation
Selzman, C. H., Shames, B. D., McIntyre, R. C., Banerjee, A. M., & Harken, A. H. (1999) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(99)00252-0 · Cited by 37
Naseem, K. M., Goodall, A. H., & Bruckdorfer, K. R. (1997) · Platelets · doi:10.1080/09537109709169333 · Cited by 33
Lambert, G. C., Chatelais, M., Petrides, F., Passard, M., Thedrez, A., Rye, K., Schwahn, U., Gusarova, V., Blom, D. J., Sasiela, W. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.07.995 · Cited by 30 · cited 1×
“They bind PCSK9 and prevent degradation of low-density lipoprotein (LDL) receptors, which increases LDL cholesterol clearance from the circulation (7, 8).”
BackgroundShen, L., Peng, H.-C., Nees, S. N., Zhao, S.-P., & Xu, D.-Y. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.02.027 · Cited by 29
Pawłowska, Z., Świątkowska, M., Krzeslowska, J., Pawlicki, L., & Cierniewski, C. S. (1993) · Atherosclerosis · doi:10.1016/0021-9150(93)90035-s · Cited by 28
Enhanced Atherosclerosis in Lp(a) WHHL Transgenic Rabbits
Fan, J., Sun, H., Unoki‐Kubota, H., SHIOMI, M., & Watanabe, T. (2001) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2001.tb03963.x · Cited by 26 · cited 1×
“Lipoprotein(a) acts as a proinflammatory mediator that can trigger atherosclerotic plaque instability (57) by enhancing inflammation through expression of adhesion molecules on endothelial cells, chemotaxis of monocytes, and proliferation of smooth-muscle cells (58, 59).”
BackgroundFischetti, D., Sciahbasi, A., Leone, A. M., Niccoli, G., Schiavoni, G., Trani, C., Mazzari, M. A., & Andreotti, F. (2000) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1026551409350 · Cited by 13 · cited 1×
“Although PCI provides greater clinical benefits than medical therapy in ACS (41), it is also associated with periprocedural events related to prothrombotic activation, distal embolization of atherothrombotic debris, reperfusion injury, and microvascular dysfunction (42, 43).”
BackgroundGüler, E., Geçmen, Ç., Güler, G. B., Karaca, O., Ağuş, H. Z., Güneş, H. M., Batgerel, U., Elveran, A., & Esen, A. M. (2013) · Kardiologia Polska · doi:10.5603/kp.2013.0156 · Cited by 13 · cited 1×
“Lipoprotein(a) acts as a proinflammatory mediator that can trigger atherosclerotic plaque instability (57) by enhancing inflammation through expression of adhesion molecules on endothelial cells, chemotaxis of monocytes, and proliferation of smooth-muscle cells (58, 59).”
BackgroundSciahbasi, A., Andreotti, F., CRISTOFARO, R. D., Fischetti, D., Leone, A. M., Schiavoni, G., Maseri, A., & Landolfi, R. (2002) · Journal of Thrombosis and Thrombolysis · doi:10.1023/a:1023232928642 · Cited by 9 · cited 1×
“Although PCI provides greater clinical benefits than medical therapy in ACS (41), it is also associated with periprocedural events related to prothrombotic activation, distal embolization of atherothrombotic debris, reperfusion injury, and microvascular dysfunction (42, 43).”
BackgroundCoronary Artery Disease: from Atherosclerosis to Cardiogenic Shock
Cheng, J. M. (2015) · RePub (Erasmus University Rotterdam) · Cited by 5
Research works printed but not linked: 1
- Virmani R, 1999, Thromb Haemost, 82, 1
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“Early preliminary data from phase III trials suggests a reduction of CV events in line with the LDL-C reduction achieved.(286,290,291) Recently, two major studies were completed: the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) and the Evaluation of Cardiovasc…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582
Qi, Z., Hu, L., Zhang, J., Yang, W., Liu, X., Jia, D., Yao, Z., Chang, L., Pan, G., Zhong, H., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.046290 · Cited by 268
Metadata
- Authors
- Navarese, E. P., Kołodziejczak, M., Kereiakes, D. J., Tantry, U. S., O'Connor, C., & Gurbel, P. A.
- Affiliations
- Inova Fairfax Hospital (US)
- From Heinrich Heine University, Düsseldorf, Germany; Systematic Investigation and Research on Interventions and Outcomes MEDICINE and Inova Heart and Vascular Institute, Fairfax, Virginia; Collegium Medicum in Bydgoszcz, University of Nicolaus Copernicus, Toruń, Poland; and Christ Hospital Heart and Vascular Center/Lindner Research Center, Cincinnati, Ohio.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-05-03
- Volume
- 164
- Issue
- 9
- Pages
- 600-607
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2305945749
- Cited by
- 77
- References
- 60
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 10 · 2023: 7 · 2022: 3 · 2021: 8 · 2020: 7 · 2019: 5 · 2018: 10 · 2017: 8 · 2016: 11
- FWCI
- 2.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- PCSK9 inhibitors, monoclonal antibodies, acute coronary syndrome, atherosclerotic plaque vulnerability, plaque composition, plaque vulnerability, dyslipidemia, pharmacokinetics, anti-inflammatory mechanism, antithrombotic mechanism
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Anti-Inflammatory Agents, Antibodies, Monoclonal, Fibrinolytic Agents, Humans, Immunologic Factors, Lipoproteins, LDL, Recurrence, Time Factors, Acute Coronary Syndrome, Plaque, Atherosclerotic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.